Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions

Conditions

• Hepatitis B, Chronic

Eligibility Criteria

Sex

ALL

Age

18 Years - 65 Years

Healthy Volunteers

Not accepted

Interventions

• AHB-137 — DRUG
  Subcutaneous injection

Study Details

This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with CHB treated with Nucleos(t)ide Analogue (NAs).

Key Dates

First listed

Jun 17, 2026

Start date

Aug 27, 2026

Status verified

Aug 2026

Primary completion

May 11, 2027

Completion

Jul 26, 2028

Study Design

Enrollment

70 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Arm A: Dose Regimen A
  Participants receive AHB-137 according to dosing regimen A.
• Experimental: Arm B: Dose Regimen B
  Participants receive AHB-137 according to dosing regimen B.

Primary Outcome Measure

Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ) [ Time Frame: 24 Weeks post AHB-137 treatment (Week 48) ]

Central Contacts

• Maggie Davis
  (650) 650-2877
  [email protected]

Locations (4)

Find similar trials in Palo Alto, CA